CompletedPhase 2NCT03832946
A Study to Test the Efficacy and Safety of Inhaled GB0139 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Studying Idiopathic pulmonary fibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Galecto Biotech AB
- Principal Investigator
- Toby Maher, MD, PhDKeck Medicine of USC
- Intervention
- GB0139(drug)
- Enrollment
- 172 enrolled
- Eligibility
- 40 years · All sexes
- Timeline
- 2019 – 2023
Study locations (30)
- SEC Clinical Research, Andalusia, Alabama, United States
- Jasper Summit Research, LLC Pulmonary & Sleep Associates, Jasper, Alabama, United States
- Palmtree Clinical Research Inc, Palm Springs, California, United States
- Paradigm Research, Redding, California, United States
- Yale University School of Medicine, New Haven, Connecticut, United States
- Health Shands Hospital, Gainesville, Florida, United States
- Harmony Medical Research Institute, Inc, Hialeah, Florida, United States
- Advanced Research for Health Improvement, Naples, Florida, United States
- Broward Research Centre, Pembroke Pines, Florida, United States
- Avanza Medical Research Centre, Pensacola, Florida, United States
- Coastal Pulmonary Critical Care PLC, St. Petersburg, Florida, United States
- Tampa General Hospital/Uni Florida, Tampa, Florida, United States
- Piedmont Healthcare Pulmonary and Critical Care Research, Atlanta, Georgia, United States
- The Emory Clinic, Atlanta, Georgia, United States
- DC Research Works, Marietta, Georgia, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Syneos Health · bioRASI, LLC
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03832946 on ClinicalTrials.govOther trials for Idiopathic pulmonary fibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT05988463Dose-Escalation Study of Artesunate Patients With IPFJoseph C. Wu
- RECRUITINGNANCT07482917Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 TrialHospital de Granollers
- RECRUITINGNANCT07486206Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 TrialHospital de Granollers
- RECRUITINGPHASE2NCT06241560A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the BloodBoehringer Ingelheim
- RECRUITINGPHASE3NCT07201922A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary FibrosisBoehringer Ingelheim
- RECRUITINGNANCT07466420Study on the Efficacy of Quercetin Intake in Patients With Fibrotic Interstitial Lung Diseases.Katerina M. Antoniou
- RECRUITINGPHASE3NCT07299695Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary FibrosisArgyrios Tzouvelekis
- RECRUITINGPHASE2NCT07284459Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary FibrosisContineum Therapeutics